Výsledky vyhledávání

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].

Autor: Fitzgerald KN; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee CH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Voss MH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Carlo MI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Knezevic A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Peralta L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chen Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lefkowitz RA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shah NJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Owens CN; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., McHugh DJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Aggen DH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Laccetti AL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kotecha RR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Feldman DR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mkscc.org.

Publikováno v: European urology [Eur Urol] 2024 Oct 18. Date of Electronic Publication: 2024 Oct 18.

Zobrazit plný text záznamu

Akademický článek

Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.

Autor: Gleeson JP; Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland.; Medical Oncology Department, Cork University Hospital, Cork, Ireland., Knezevic A; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY., Bromberg M; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY., Patil S; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY., Sheinfeld J; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Carver BS; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Bains M; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Jones DR; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Bajorin DF; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Bosl GJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., McHugh DJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Funt SA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Motzer RJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Feldman DR; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 10; Vol. 42 (26), pp. 3130-3139. Date of Electronic Publication: 2024 Jul 19.

Zobrazit plný text záznamu

Akademický článek

Oxygen-enhanced MRI detects incidence, onset and heterogeneity of radiation-induced hypoxia modification in HPV-associated oropharyngeal cancer.

Autor: Dubec MJ; University of Manchester, Manchester, United Kingdom., Price J; The Christie NHS Foundation Trust, Manchester, United Kingdom., Berks M; University of Manchester, Manchester, United Kingdom., Gaffney J; The Christie NHS Foundation Trust, United Kingdom., Little RA; University of Manchester, Manchester, United Kingdom., Porta N; Institute of Cancer Research, Sutton, Surrey, United Kingdom., Sridharan N; Institute of Cancer Research, United Kingdom., Datta A; University of Manchester, Manchester, United Kingdom., McHugh DJ; University of Manchester, Manchester, United Kingdom., Hague CJ; The Christie NHS Foundation Trust, United Kingdom., Cheung S; University of Manchester, Manchester, United Kingdom., Manoharan P; The Christie NHS Foundation Trust, Manchester, United Kingdom., van Herk M; University of Manchester, Manchester, United Kingdom., Choudhury A; University of Manchester, Manchester, United Kingdom., Matthews JC; University of Manchester, Manchester, United Kingdom., Parker GJM; University College London, London, United Kingdom., Buckley DL; University of Leeds, Leeds, West Yorkshire, United Kingdom., Harrington KJ; Institute of Cancer Research, London, United Kingdom., McPartlin A; Princess Margaret Cancer Centre, Canada., O'Connor JPB; Institute of Cancer Research, Sutton, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 15. Date of Electronic Publication: 2024 Aug 15.

Zobrazit plný text záznamu

Akademický článek

Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.

Publikováno v: European urology [Eur Urol] 2024 Aug; Vol. 86 (2), pp. 90-94. Date of Electronic Publication: 2024 May 22.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání